Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Target Validation, 2012
    Validation of ATP13a2 / PARK9 as a Target to Reduce Neurodegeneration Induced by Alpha-Synuclein

    Objective/Rationale:
    Alpha-synuclein plays a prominent role in Parkinson’s disease and identifying valid targets to ameliorate the neurodegenerative effects of alpha-synuclein is a major therapeutic...

  • Clinical Intervention Awards, 2012
    Phase I Study of AAV2-hAADC Administered by MRI-guided Real-time Convective Infusion

    Objective/Rationale:
    The purpose of this study is to provide safety data related to enhancements in the clinical delivery procedure for administering Adeno-Associated Virus Encoding Human Aromatic L...

  • Repositioning Drugs for PD, 2012
    Amitriptyline as a Dopamine Neuroprotective Therapy

    Objective/Rationale:
    The project proposes to repurpose the tricyclic antidepressant medication, amitriptyline (AMI), as a disease-modifying therapy for Parkinson’s disease (PD). AMI is an FDA-approved...

  • Neurotrophic Factors Challenge, 2012
    Validation of IGF-1 as a Neuroprotective Agent in Pre-clinical Models of Parkinson’s Disease
    Objective/Rationale: IGF-1-mediated intracellular signaling pathways engage a wide range of potential survival mechanisms, the PI3K/Akt pathway and the ER stress response in particular, and it has...
  • Rapid Response Innovation Awards, 2012
    Is Parkinson’s Disease a Low-grade Inflammatory Bowel Disease?

     

    Objective/Rationale:
    Central and peripheral inflammations are likely to be critical in the initiation and/or development of PD. Data from recent genetic studies suggest a link between PD and gut...

  • Repositioning Drugs for PD, 2012
    Atomoxetine for Cognitive Impairment in Parkinson’s Disease

    Objective/Rationale:
    Parkinson’s disease (PD) causes well known motor symptoms of tremor, slowness and stiffness, but also leads to cognitive impairment. Research has shown that early loss of cells in...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.